Brazilian Reality of Hepatocellular Carcinoma - BRA-HEP

Study identifier:D133HR00024

ClinicalTrials.gov identifier:NCT06230328

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Brazilian Reality of Hepatocellular Carcinoma - BRA-HEP: Multicenter Retrospective Study (Real World Evidence - RWE)

Medical condition

Hepatocellular Carcinoma

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

300

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 15 Apr 2024
Estimated Primary Completion Date: 30 Nov 2024
Estimated Study Completion Date: 30 Nov 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Hospital Israelita Albert Einstein

Inclusion and exclusion criteria